ArticleBiomarker research2026
Epigenetic biomarkers of progestin-resistance in endometriosis.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The hypoxia-epigenetics-ncRNA axis in endometriosis: from molecular cascades to self-sustaining pathogenic circuits.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEndometriosis is a heterogeneous, estrogen-dependent inflammatory disorder that affects up to 15% of reproductive age women. Progestin-based therapies are the most commonly prescribed initial treatment; however, approximately one-third of patients exhibit progestin resistance, leading to inadequate symptom relief and discontinuation. Given the role of epigenetic dysregulation in endometriosis and its impact on hormonal responsiveness, we aimed to identify if circulating leukocyte DNA methylation signatures were associated with progestin treatment response and could serve as a non-invasive predictive biomarker.
methodsWe conducted a prospective cohort study of 31 women with surgically confirmed endometriosis, categorized as progestin responders (n = 10) or non-responders (n = 21) based on clinical outcomes. Buffy coat-derived leukocytes were processed for whole-genome methylation analysis using enzymatic methyl-seq. Differentially methylated CpG sites were identified using logistic regression, and candidate genes were subject to Receiver Operating Curve analysis. A stepwise logistic regression model was developed to identify the minimal methylation gene set predictive of treatment response. Internal validation included permutation and bootstrap testing.
resultsResponders and non-responders did not differ significantly in baseline demographics or clinical variables. There were 1,439 genes that were significantly differentially methylated between responders and non-responders. A three-gene methylation signature, MMP20, NRXN1, and RNA5-8SN5, distinguished responders from non-responders with high accuracy (ROC AUC = 0·952). Internal validation confirmed model robustness (bootstrap AUC = 0·907, 95% CI: 0·80–0·957; permutation p < 0·001).
conclusionCirculating leukocyte methylation profiles can serve as noninvasive biomarkers of progestin responsiveness in endometriosis. Our findings suggest that blood-based epigenetic profiling may inform personalized treatment decisions, avoiding prolonged treatment with ineffective therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.